November 01, 2025

Get In Touch

COVID Survivors Lose Vision To Black Fungus Mucormycosis In Gujarat

Mucormycosis Cases in Gujarat

Mucormycosis Cases in Gujarat

New Delhi: Cases of Mucormycosis, a fungal infection, affecting some COVID-19 survivors are on the rise in Gujarat which has left many patients blind, doctors and officials claimed on Saturday.

Mathur Savani, chairman of Surat-based Kiran Super multi-speciality hospital, said mucormycosis was detected in a patient who had recovered from COVID-19 disease around three weeks back.

Also Read: Bharat Serums gets DCGI nod to covid linked black fungus drug

"This number has gone up to around 50 now while 60 more such patients are awaiting treatment," Savani told PTI.

The hospital, which is managed by a trust, has been receiving several patients diagnosed with Mucormycosis who are being referred from various areas in Surat and other parts of Gujarat, he said.

"As of now, 50 mucormycosis patients are getting treated at Kiran Hospital and 60 others are awaiting (treatment). They all came to our hospital in the last three weeks. All the patients who are suffering from mucormycosis had recovered from COVID-19 recently," said Savani.

According to Savani, seven such patients have lost their eyesight so far.

Meanwhile, considering the growing number of patients with mucormycosis, Surat's civil hospital has set up a separate facility for their treatment, said in-charge Resident Medical Officer (RMO) Dr Ketan Naik.

He said a separate facility with the dedicated medical staff has been created which will soon start treating patients with mucormycosis.

In Ahmedabad, at least five patients with mucormycosis are being operated upon every day at the civil hospital at Asarva, a senior doctor said.

"In Ahmedabad, we are receiving 5 to 10 such cases at the civil hospital, especially since the second wave of COVID-19 started. These patients are being examined on priority and operated on as early as possible," said Dr Devang Gupta, ENT doctor at the city civil hospital.

He said various resources, including manpower, equipment and injection required for the treatment of mucormycosis patients, have been provided by the government.

"At least one out of the five such cases is related to eyes. Several of them (patients) are suffering from blindness," he said.

Niti Aayog Member (Health) V K Paul on Friday said mucormycosis is being found in patients with COVID-19 disease.

"It is caused by a fungus named mucor, which is found on wet surfaces. It, to a large extent, is happening to people who have diabetes. It is very uncommon in those who are not diabetic. There is no big outbreak and we are monitoring it," he had said.

According to Dr Paul, mucor attacks people with uncontrolled sugar.

He had also said when the same COVID-19 patient is put on oxygen support, which has a humidifier containing water, the chances of him or her getting the fungal infection increase.

As of May 7, Gujarat's COVID-19 tally stood at 6,58,036 while the overall toll is 8,154. The total count of recoveries stood at 5,03,497.

Also Read: IT norms eased: Govt permits cash payment of over Rs 2 lakh for COVID-19 Treatment at hospitals

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!